ADAP stock: buy or sell?
May 22nd, 2020
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.
Should I buy ADAP stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading plan that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Check the only buy setup that matches with Adaptimmune Therapeutics stock now:
|New all-time high||No|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Adaptimmune stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for ADAP stock for the last month.
ADAP stock analysis
After boosting an exceptional 6.81% on Thursday, Adaptimmune closed on May 22nd at $5.77 and eased a tragic -1.70%.
After boosting an exceptional 6.81% on Thursday, Adaptimmune closed on May/22 at $5.77 and eased a tragic -1.70%. Since SMA100d and SMA200d crossed up on March, ADAP price climbed $3.00 per share (108.30%). Since price and SMA200d lines crossed up on March, ADAP climbed $3.52 (156.44%). ADAP shows a sign of strength in the short-term after finally breaking out above $5.08 on May/12 and marking a new rising bottom.
Adaptimmune Therapeutics shares climbed 24.09% this week, ending at $5.77. Late March ADAP plunged a chilling -8.37% in just one week. For 3 weeks in a row, price climbed and marked a profit of 70.14%.
Price finally broke over the resistance at $3.87 and continued climbing. Early March, SMA20w and SMA40w crossed up triggering a rise of 65.33%. Since mid January when ADAP stock price broke up the SMA40w line, it gained $4.44 (333.83%).
ADAP stock price history
ADAP stock went public on May 6th, 2015 with a price of $19.251. Since then, ADAP stock declined a -70.00%, with a yearly average of -14.00%.
1: Adjusted price after possible price splits or reverse-splits.
ADAP stock historical price chart
ADAP stock reached 52-week highs on May 22nd at $6.05, and all-time highs 2015-06-16 with a price of 21.57.
ADAP stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price forecast for Adaptimmune stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Adaptimmune Therapeutics reported its latest financial data, posting an extraordinary growth for the Earnings per Share (EPS). Experts were expecting $-0.29 per share, but Adaptimmune Therapeutics posted $-0.36.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Adaptimmune annual revenues boosted a super good 57.28% to $59.51 M USD from $37.83 marked in 2017. In line, its earnings margin (compared to sales) skyrocketed to -160.51%, that is $-95.51 million.
|2014||$825 M||-||$0.00 M0.0%||-|
|2014||$0.58 M||-99.93%||$-12.21 M-2100.9%||0.00%|
|2015||$9.87 M||1,598.45%||$-22.06 M-223.5%||80.66%|
|2015||$8.98 M||-9.04%||$-23.00 M-256.2%||4.27%|
|2016||$14 M||58.12%||$-71.58 M-504.1%||211.21%|
|2017||$38 M||166.47%||$-70.14 M-185.4%||-2.01%|
|2018||$60 M||57.28%||$-95.51 M-160.5%||36.18%|
Quarterly financial resultsAdaptimmune reported $1.48 million in revenues for 2018-Q4, a -96.37% less compared to previous quarter. Reported quarter income marked $-36.17 M with a profit margin of -2,445.77%. Profit margin plunged a -2,458.62% compared to previous quarter when profit margin was 12.85%. When comparing sales to same quarter last year, Adaptimmune Therapeutics sales marked a frightening decrease and collapsed a -65.36%.
|2017-Q1||$3 M||-||$-21.99 M-763.5%||-|
|2017-Q2||$4 M||23.61%||$-20.44 M-574.2%||-7.05%|
|2017-Q3||$27 M||663.62%||$-0.88 M-3.2%||-95.70%|
|2017-Q4||$4 M||-84.29%||$-27.26 M-638.5%||3,005.13%|
|2018-Q1||$8 M||91.94%||$-21.08 M-257.2%||-22.69%|
|2018-Q2||$9 M||10.27%||$-43.85 M-485.1%||108.01%|
|2018-Q3||$41 M||351.34%||$5.24 M12.9%||-111.96%|
|2018-Q4||$1 M||-96.37%||$-36.17 M-2445.8%||-790.06%|
Adaptimmune ownershipReviewing Adaptimmune Therapeutics ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Adaptimmune Therapeutics, 0.20% of all outstanding shares are owned by its staff.
In case of Adaptimmune stock, 50.74% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ADAP stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$747.3 M|
|Total shares||129.5 M|
|Float shares||64.8 M|
|- Institutional holdings (%)||50.7%|
|- Insider holdings (%)||0.2%|
|Shares in short selling||0.0%|
|Friday, May 22nd, 2020|
|Day range||$5.55 - $6.05|
|Average true range||$0.65|
|50d mov avg||$3.53|
|100d mov avg||$3.48|
|200d mov avg||$2.38|
Adaptimmune performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Adaptimmune Therapeutics, the benchmark is made against .